Baxter International (BAX) Earnings Announcement Scheduled for This Friday

Baxter International (NYSE:BAX) is planning to release its quarterly earnings report prior to the market opening on Friday, November 8th. Analysts anticipate that the company will report earnings of $0.78 per share for the upcoming quarter. Individuals interested in joining the company’s conference call can find access through the provided link.

In its most recent earnings release on August 6th, Baxter International reported earnings of $0.68 per share, which exceeded analysts' expectations of $0.66 by $0.02. The company achieved a return on equity of 18.06% and a net margin of 16.51%. During that quarter, Baxter International ended with revenues of $3.81 billion, surpassing the consensus forecast of $3.75 billion. This represents a 2.8% increase in revenue compared to the same period last year, when the company reported earnings of $0.55 per share. Analysts expect that Baxter International will generate earnings of $3.00 per share for both the current and next fiscal years.

Baxter International Stock Performance

As of Friday, Baxter International’s stock opened at $35.70. The company possesses a quick ratio of 0.91, a current ratio of 1.40, and a debt-to-equity ratio of 1.35. The stock has traded between a 12-month low of $32.06 and a high of $44.01. Currently, Baxter International has a fifty-day simple moving average of $37.64 and a 200-day simple moving average of $36.29. The company’s market capitalization stands at $18.21 billion, with a price-to-earnings (P/E) ratio of 7.35 and a price-to-earnings-growth (PEG) ratio of 1.28. Additionally, the stock has a beta of 0.59, indicating lower volatility compared to the broader market.

Recent Analyst Ratings on Baxter International

Recent analyst reports on Baxter International have highlighted varying opinions on the stock. Notably, Morgan Stanley downgraded Baxter from an “equal weight” to an “underweight” rating, adjusting their price target for the stock from $39.00 to $30.00 as of July 15th. Meanwhile, JPMorgan Chase & Co. also cut their target price from $44.00 to $42.00 and maintained a “neutral” rating as of August 7th. StockNews.com upgraded Baxter International from a “hold” to a “buy” rating on October 22nd, while Goldman Sachs increased their target price from $36.00 to $40.00, also giving a “neutral” rating in a report on August 8th. Additionally, Wells Fargo lowered their target price from $44.00 to $40.00, maintaining an “equal weight” rating. Currently, one analyst has assigned a sell rating, while seven have issued holds and three have expressed a buy rating for the company. The consensus rating for Baxter International stands at “Hold” with an average price target of $41.20 according to MarketBeat.

Overview of Baxter International

Baxter International Inc., through its subsidiaries, develops and offers a range of healthcare products on a global scale. The company operates through four main segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. Their product line includes sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, generic injectable pharmaceuticals, surgical hemostat and sealant products, advanced surgical equipment, smart bed systems, patient monitoring technologies, as well as respiratory health devices. They also provide state-of-the-art equipment for surgery, including surgical video technologies and precision positioning devices.

Earnings, Stocks, Analysis